Lymphatic Diseases  >>  Torisel (temsirolimus)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Torisel (temsirolimus) / Pfizer
OPTIMAL, NCT00117598: Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)

Checkmark P3 data - EHA
May 2012 - May 2012: P3 data - EHA
Checkmark P3 data
Dec 2011 - Dec 2011: P3 data
Completed
3
169
US, Canada, Europe, RoW
Temsirolimus (CCI-779), Investigator's choice
Pfizer
Lymphoma
08/07
01/11
RAY , NCT01646021 / 2012-000601-74: Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy

Checkmark Final 3-year follow-up results from the RAY P3 trial
May 2018 - May 2018: Final 3-year follow-up results from the RAY P3 trial
Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Checkmark Vs. temsirolimus in patients with relapsed or refractory mantle-cell lymphoma
More
Completed
3
280
Canada, Europe, RoW
Ibrutinib, Temsirolimus
Janssen Research & Development, LLC, Pharmacyclics LLC.
Mantle Cell Lymphoma
06/15
12/16

Download Options